Entering text into the input field will update the search result below

ATNF 180 Life Sciences Corp.
Stock Price & Overview

$0.300.01 (+4.56%)3:59 PM 12/04/23
NASDAQ | $USD | Post-Market: $0.30 +0.01 (+2.87%) 7:58 PM


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

People Also Follow

Company Profile

180 Life Sciences Corp. logo
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
  • Building 4
  • Suite 200
  • 3000 El Camino Real
  • Palo Alto, CA, 94306
  • United States
Phone Number
650 507 0669
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.